Valeant's Permax No Longer Permitted In The U.S. For Parkinson's Disease
This article was originally published in The Pink Sheet Daily
FDA announces voluntary withdrawal of the pergolide brand and two generics due to high rates of cardiac valvulopathy.
You may also be interested in...
Valeant adds the Parkinson's therapy Permax (pergolide) to its CNS business with the acquisition of Amarin Corp.'s U.S. pharma business, announced Feb. 12
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.